Ann: Clinical milestones for 2024 & 2023 successes highlighted, page-5

https://clinicaltrials.gov/study/NCT06055439?intr=cdh17&aggFilters=status:not&rank=2

This trial will be the catalyst for share price appreciation.

I'm keen for others thoughts on this one but it looks to me like they're planning on having the phase 2 primary completion wrapped up by mid 2026. That's a lot quicker than I anticipated and an enormous amount of confidence before they have dosed a single patient. Looking at the study overview, the estimated enrolment number of 135 patient's and the phases 1 and 2 listed would suggest as much?

Given the preclinic complete eradication of all cancer cells happened within a month, the preliminary data back end of the year is going to be of HUGE interest.